/PRNewswire/ Verseon is pleased to announce that the USPTO has issued a new patent, "Thrombin Inhibitors, Formulations, and Uses Thereof," that further.
Verseon Gain US Patent Protection for Compounds that Could Eliminate Bleeding Risks of Current Anticoagulants“They could radically improve the standard of care for several hundred million underserved patients around the world,” says Verseon’s CSO David KitaFremont, Calif.— Verseon is pleased.
Verseon is delighted to announce that the European Journal of Medicinal Chemistry has published a paper (www.sciencedirect.com/science/article/abs/pii/S0223523422007577) describing the company's groundbreaking research that led to promising novel drug candidates for cardiovascular disease. Cardiovascular disease is the leading cause of death and disability in the world. Hundreds of millions of patients worldwide need anticoagulants to prevent